CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemiaYannis K. Valtis, Jae H. Park, Xiuyan Wang et al.|Blood Advances|2025Cited by 3
KMT2Ar Adversely Impacts Brexucabtagene Autoleucel (Brexu-cel) Outcome in Adults with Relapsed/ Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia.Abdullah Ladha, Caspian Oliai, Virginia Tan et al.|Transplantation and Cellular Therapy|2025Cited by 1
NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free SurvivalYannis K. Valtis, Aaron C. Logan, David Nemirovsky et al.|Transplantation and Cellular Therapy|2025Cited by 0